A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.
Resecting GIST tumors may improve survival rates. Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy
The Life Raft Group is dedicated to the welfare and survival of GIST patients worldwide and we carry out our mission through research, patient support & education and advocacy. The LRG was highlighted in all three areas at the end of 2012 and we wanted to share the important work we’re doing with all of you.
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.
Dr. Peter Reichardt presented a retrospective study wherein sorafenib showed significant clinical activity in resistant metastatic GIST patients.
By Jonathan Fletcher, M.D. & Sebastian Buaer, M.D. Within the past decade, GISTs have emerged from being poorly defined, treatment-resistant tumors to a well recognized, well understood, and treatable tumor entity. Rapid advances in the understanding [...]
Here is a video on Serum Imatinib (Gleevec) Levels Predict GIST Response. George D. Demetri, M.D., discusses how Gleevec levels predict GIST response. Higher circulating levels of imatinib (Gleevec) correlated with better clinical responses in patients with [...]
Thirteen GIST abstracts were presented this year at the 2008 Gastrointestinal Cancers Symposium, sponsored by the American Society of Clinical Oncology (ASCO). Space limitations will not permit us to report on all of these abstracts.
